Author

Omoniyi J. Adedokun 1

1 Janssen Research & Development, LLC

EARLY PRO-2 SYMPTOM REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY

William J. Sandborn, Tadakazu Hisamatsu, Kathleen Weisel, Susana Gonzalez, Mary Ellen Frustaci, Zijiang Yang, Jewel Johanns, Matthew Germinaro, Brian Feagan, Aniita Afzali, Walter Reinisch, Jane Andrews, Omoniyi J. Adedokun, Chenglong Han

EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE THROUGH 5 YEARS: FINAL RESULTS FROM THE IM-UNITI LONG-TERM EXTENSION

William Sandborn, Paul Rutgeerts, John Lynch, Rory Rebuck, Yuhua Wang, Bin Zou, Christopher Gasink, Omoniyi J. Adedokun, Bruce E. Sands, Stephen B Hanauer, Stephan Targan, Subrata Ghosh, Willem de Villiers, Jean-Frederic Colombel, Brian G. Feagan

PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY

Omoniyi J. Adedokun

PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY

Omoniyi J. Adedokun, Remo Panaccione, Tadakazu Hisamatsu, Maria T. Abreu, Rupert W.L. Leong, David Rowbotham, Colleen W. Marano, Yiying Zhou, Hongyan Zhang, Silvio Danese, Waqqas Afif, Laurent Peyrin-Biroulet, William Sandborn, Bruce E. Sands

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY

Geert D’Haens, Omoniyi J. Adedokun, Silvio Danese, Severine Vermeire, Julian Panés, Axel Dignass, Fernando Jose Magro Dias, Maciek Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Daniel R. Gaya, Laurent Peyrin-Biroulet

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE–RESPONSE RELATIONSHIPS OF USTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGET VS STANDARD OF CARE ANALYSIS OF THE STARDUST STUDY

Silvio Danese, Severine Vermeire, Geert R. D'Haens, Omoniyi J. Adedokun, Julian Panés, Axel Dignass, Fernando Magro, Maciej Nazar, Marjolein Lahaye, Manuela Le Bars, Lioudmila Ni, Daniel R. Gaya, Ivana Bravata, Laurent Peyrin-Biroulet

THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 INTERIM ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY

William Sandborn, Daphne Chan, Jewel Johanns, Grace Lang, Omoniyi J. Adedokun, Anita Afzali, Jane Andrews, Geert R. D'Haens, Silvio Danese, Tadakazu Hisamatsu, Remo Panaccione, Julian Panés, Walter Reinisch, David T. Rubin, Bruce E. Sands, Brian G. Feagan

THE PHARMACOKINETICS AND IMMUNOGENICITY OF USTEKINUMAB AND ADALIMUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE SEAVUE STUDY

Silvio Danese, James Izanec, Tony Ma, Omoniyi J. Adedokun, Christopher Gasink, Stephen B Hanauer, Ellen Scherl, Kamal Patel

TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL

Geert R. D'Haens, Silvio Danese, Severine Vermeire, Julian Panés, Axel Dignass, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravatà, Omoniyi J. Adedokun, Daniel R. Gaya, Laurent Peyrin-Biroulet

USTEKINUMAB DRUG EXPOSURE IS NOT LINKED TO CHANGES IN BOWEL WALL THICKNESS, BUT DOES ASSOCIATE WITH TRANSMURAL REMISSION IN CROHN’S DISEASE

Bram Verstockt, Christian Maaser, Rune Wilkens, Giovanni Maconi, Maria Antonietta D’Agostino, Maciej Nazar, Marjolein Lahaye, Omoniyi J. Adedokun, Manuela Le Bars, Ivana Bravatà, Lioudmila Ni, Mariangela Allocca, Floris A. E. de Voogd, Carolina Palmela, Rose Vaughan, Torsten Kucharzik

Item 1 - 10 / 10
1